Experimental cancer vaccine combo shows promise in small trial
NCT ID NCT03789097
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This early-phase trial tested a combination of four therapies to train the immune system to attack cancer. 17 adults with non-Hodgkin's lymphoma, metastatic breast cancer, or head and neck cancer received low-dose radiation, an immune cell booster (Flt3L), an immune activator (Poly-ICLC), and the immunotherapy pembrolizumab. The goal was to see if this 'in situ vaccine' approach was safe and could shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.